Phase 2 Recruiting Network
This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05040360
Sites in Rhode Island: - Smilow Cancer Hospital Care Center - Westerly — Westerly, Rhode Island
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in partici…
Sponsor: Genentech, Inc.
NCT ID: NCT05968326
Sites in Rhode Island: - Rhode Island Hospital — Providence, Rhode Island
- Miriam Hospital — Providence, Rhode Island
Phase 2 Recruiting Industry
The purpose of the study is to assess the efficacy and safety of Acoustic Cluster Therapy (ACT) when given in addition to chemotherapy for treatment of Locally Advanced Pancreatic Cancer.
Sponsor: EXACT Therapeutics AS
NCT ID: NCT06850623
Sites in Rhode Island: - Brown University Cancer Institute — Providence, Rhode Island
Phase 2 Recruiting Industry
The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer agents in participants with locally advanced unresectable or…
Sponsor: AstraZeneca
NCT ID: NCT06219941
Sites in Rhode Island: - Research Site — Providence, Rhode Island
Phase 2 Recruiting Academic/Other
The purpose of this study is to determine if combination treatment with cemiplimab, motixafortide, gemcitabine, and nab-paclitaxel is effective in decreasing the size of the tumor(s), if it will prolong life in patients, and if it's safe. …
Sponsor: Gulam Manji
NCT ID: NCT04543071
Sites in Rhode Island: - Brown University — Providence, Rhode Island
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD4360 in adult participants with locally advanced or metastatic solid tumours selected for expression of…
Sponsor: AstraZeneca
NCT ID: NCT06921928
Sites in Rhode Island: - Research Site — Providence, Rhode Island
Phase 1 Recruiting Industry
The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This study also aims to find the best dose. This study is seeking participants who have…
Sponsor: Pfizer
NCT ID: NCT06447662
Sites in Rhode Island: - Rhode Island Hospital — Providence, Rhode Island
- Miriam Hospital — Providence, Rhode Island
Phase 1 Recruiting Industry
This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of JAN…
Sponsor: Janux Therapeutics
NCT ID: NCT05783622
Sites in Rhode Island: - Rhode Island Hospital — Providence, Rhode Island
Phase 1 Recruiting Industry
The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driv…
Sponsor: Bicara Therapeutics
NCT ID: NCT04429542
Sites in Rhode Island: - Rhode Island Hospital — Providence, Rhode Island
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Rhode Island: - Providence Veterans Administration Hospital — Providence, Rhode Island
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Rhode Island: - Massive Bio SYNERGY-AI site — Providence, Rhode Island